Allowing Greater Access to Safe and Effective Contraception Act
This bill requires the Food and Drug Administration (FDA) to prioritize review of supplemental drug applications (applications to modify the approved use of a drug) for contraceptive drugs intended for routine use that would be available to individuals aged 18 and older without a prescription. The FDA must waive user fees for such supplemental drug applications. Any drug that is eligible for this priority review must be a prescription drug for individuals under age 18.
This bill repeals provisions of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 to allow health savings accounts and health flexible spending accounts (HFSAs) to be used to pay for medicine without a prescription and to remove the limit on salary reduction contributions to a HFSA under a cafeteria plan, effective as if the provisions had never been enacted.
[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 421 Introduced in House (IH)]
<DOC>
115th CONGRESS
1st Session
H. R. 421
To allow women greater access to safe and effective contraception.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
January 10, 2017
Mrs. Love (for herself, Mrs. Comstock, Mr. Stewart, Mr. Coffman, and
Mr. Kinzinger) introduced the following bill; which was referred to the
Committee on Ways and Means, and in addition to the Committee on Energy
and Commerce, for a period to be subsequently determined by the
Speaker, in each case for consideration of such provisions as fall
within the jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To allow women greater access to safe and effective contraception.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Allowing Greater Access to Safe and
Effective Contraception Act''.
SEC. 2. APPLICATIONS FOR NON-PRESCRIPTION CONTRACEPTIVE DRUGS.
(a) Priority Review of Application.--The Secretary of Health and
Human Services (referred to in this section as the ``Secretary'') shall
give priority review to any supplemental application submitted under
section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
355(b)) for a contraceptive drug, provided that--
(1) the supplemental application is with respect to a drug
intended for routine use; and
(2) if the supplemental application is approved, with
respect to individuals aged 18 and older, such drug would not
be subject to section 503(b)(1) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 353(b)(1)).
(b) Fee Waiver.--The Secretary shall waive the fee under section
736(a)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
379h(a)(1)) with respect to a supplemental application that receives
priority review under subsection (a).
(c) Over-the-Counter Availability.--Notwithstanding any other
provision of law, with respect to individuals under age 18, a
contraceptive drug that is eligible for priority review under
subsection (a) shall be subject to section 503(b)(1) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)(1)).
SEC. 3. EMPOWERING WOMEN TO MAKE THEIR OWN HEALTH DECISIONS.
(a) No Limitations Based on Whether a Drug Is Prescribed.--Section
9003 of the Patient Protection and Affordable Care Act (Public Law 111-
148), and the amendments made by such section, are repealed, and the
Internal Revenue Code of 1986 shall be applied as if such section, and
amendments, had never been enacted.
(b) No Limitations on Health FSAs.--Sections 9005 and 10902 of the
Patient Protection and Affordable Care Act (Public Law 111-148) and
section 1403 of the Health Care and Education Reconciliation Act of
2010 (Public Law 111-152), and the amendments made by such sections,
are repealed, and the Internal Revenue Code of 1986 shall be applied as
if such sections, and amendments, had never been enacted.
<all>
Introduced in House
Introduced in House
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line